Today, MDbiotogether with their research partners at Radicle Science, announce the initiation of three separate clinical trials evaluating the effectiveness of individual products targeting insomnia, pain and stress. The purpose of the clinical studies is to understand the effectiveness of three new herbal compounds MDbio products. During the studies, physicians will test synergistic results in multi-active formula compounds and determine the effect of drug vacations with herbal medicines. MDbio will test its current product range; MDsleep™, MDrelief™ and MDcalm™ in over 2,500 US adults. The trials last 4 weeks, with the first trial starting in August. All three products have already successfully completed extensive internal observation studies, some of which have been tested on patients from our own practice with the relevant disease.
“We are pleased to work with Dr. Chen and his colleagues to work together to obtain data from large-scale efficacy studies on our current product portfolio. Your team embodies our commitment to developing products backed by real science and working with our patients and customers to continually refine and improve our product offering. Today, we continue our investment in the development of safe and effective medicines,” said Brenden Dougherty, Chief Executive at MDbio.
The results of the highly anticipated clinical studies are expected to be available to the public in the first quarter of 2023. MDbio currently sells all three products for purchase on their own website.
MDbio is a herbal products company that offers safe,
Founded by four award-winning physicians with distinguished and successful careers in America’s leading hospitals and medical centers. MDbio develops products that restore the body’s balance (homeostasis) during periods of insomnia, anxiety, pain and other common situations. Our doctors not only want to give patients back well-being, but also a true “joy of…
